Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP11851-pAAV-hDLX-minBG-iCre-4X2C-WPRE3-BGHpA (Alias: CN1851) (#164450). In addition to the viral particles, you will also receive purified AiP11851-pAAV-hDLX-minBG-iCre-4X2C-WPRE3-BGHpA (Alias: CN1851) plasmid DNA. minBetaGlobin-driven expression of Cre in forebrain GABAergic interneurons. For use in combination with Cre-dependent transgenic mouse lines or co-infection with Cre dependent viral vectors. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.